1. |
Bisphosphonates: are they useful in breast cancer? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1364,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1364,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
Nifedipine use remains high in the Czech Republic |
|
Inpharma Weekly,
Volume &NA;,
Issue 1364,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Moxifloxacin cost effective versus ceftriaxone in AECB |
|
Inpharma Weekly,
Volume &NA;,
Issue 1364,
2002,
Page 5-5
Cameron Johnston,
Preview
|
|
摘要:
A 5-day course of oral moxifloxacin has been shown in an Italian multicentre study to be at least as clinically effective, and more cost effective, than a 7-day course of IM ceftriaxone for treating patients with acute exacerbations of chronic bronchitis (AECB). This is an important finding given that the incidence of AECB is likely to rise as the world's population ages, and the number of people who smoke does not appear to be declining to any significant degree. Therefore, studies will be needed to help rationalise drug choices for patients with AECB, with the rationalisations focusing on efficacy, safety, ease of administration and cost effectiveness.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1364,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1364,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1364,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
Roflumilast promising in COPD and asthma |
|
Inpharma Weekly,
Volume &NA;,
Issue 1364,
2002,
Page 9-10
Raewyn Poole,
Preview
|
|
摘要:
The orally active phosphodiesterase IV inhibitor roflumilast is effective in the treatment of asthma and chronic obstructive pulmonary disease (COPD), according to data from clinical studies presented at the 12th Annual Meeting of the European Respiratory Society [Stockholm, Sweden; September 2002]. Roflumilast demonstrated dose-dependent activity in the treatment of asthma, and had efficacy comparable to beclomethasone. A study involving patients with COPD also demonstrated favourable efficacy and tolerability.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1364,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Alicaforsen beneficial in Crohn's disease? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1364,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|